NCT00381654View on ClinicalTrials.gov

Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

February 28, 2010

Conditions
Tumor
Interventions
DRUG

AV-412

Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)

Trial Locations (3)

21205

Johns Hopkins University School of Medicine, Baltimore

Unknown

Hospital Universitatrio Austral, Buenos Aires

Instituto Médico Especializado Alexander Fleming, Buenos Aires

Sponsors
All Listed Sponsors
lead

AVEO Pharmaceuticals, Inc.

INDUSTRY